This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
androgen-receptor
Androgen Receptor
Nuclear receptor activated by testosterone and DHT; ligand binding → nuclear translocation → androgen response elements → PSA and TMPRSS2 induction. Amplified and mutated in castration-resistant prostate cancer; enzalutamide, apalutamide, and abiraterone target the AR pathway.
Entry Metadata
| Field | Value |
|---|---|
| ID | androgen-receptor |
| Name | Androgen Receptor |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-433. · PubMed 24881730
- Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-148. · PubMed 23228172